Literature DB >> 9456252

Impact of opportunistic disease on survival in patients with HIV infection.

R E Chaisson1, J E Gallant, J C Keruly, R D Moore.   

Abstract

OBJECTIVE: To assess the impact of opportunistic diseases on survival in patients with HIV disease.
METHODS: A cohort of 2081 patients followed for a mean of 30 months was studied. Time-dependent Cox proportional hazards analyses were performed using incident opportunistic diseases and CD4 cell counts as independent variables.
RESULTS: During follow-up, 730 (35%) patients died. The occurrence of Pneumocystis carinii pneumonia (PCP), cytomegalovirus (CMV) disease, Mycobacterium avium complex (MAC) disease, Candida esophagitis, Kaposi's sarcoma, lymphoma, progressive multifocal leukoencephalopathy (PML), dementia, wasting, toxoplasmosis, and cryptosporidiosis were all significantly associated with death, independently of CD4 cell count (all P<0.001 for opportunistic diseases controlling for CD4 cell count). The magnitude of increased risk was greatest for lymphoma [relative hazard (RH), 7.2], PML (RH, 3.9), MAC (RH, 3.0) and CMV (RH, 2.2). Cryptococcosis (RH, 0.94) and herpes zoster (RH, 0.85) were not associated with death. In a multivariate Cox proportional hazards analysis, MAC [RH, 2.56; 95% confidence interval (CI), 2.1-3.1], CMV (RH, 1.63; 95% CI, 1.3-2.1), toxoplasmosis (RH, 1.85; 95% CI, 1.3-2.6), PCP (RH, 1.29; 95% CI, 1.1-1.5), and CD4 cell count were significantly associated with death. Patients who had opportunistic diseases had significantly greatly monthly declines in CD4 counts (-11 x 10(6)/l per month) than those who did not (-6 x 10(6)/l per month; P <0.001).
CONCLUSION: Most opportunistic diseases increase the risk of death independently of CD4 cell count. These data support the hypothesis that opportunistic diseases enhance HIV pathogenesis and further underscore the importance of prophylaxis.

Entities:  

Mesh:

Year:  1998        PMID: 9456252     DOI: 10.1097/00002030-199801000-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  25 in total

1.  Analysis of a population-based Pneumocystis carinii pneumonia index as an outcome measure of access and quality of care for the treatment of HIV disease.

Authors:  Peter S Arno; Marc N Gourevitch; Ernest Drucker; Jing Fang; Clara Goldberg; Margaret Memmott; Karen Bonuck; Nandini Deb; Ellie Schoenbaum
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

2.  Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease: Aquitaine Cohort, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).

Authors:  C Binquet; F Saillour; N Bernard; M B Rougier; F Leger; F Bonnal; F Dabis
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

3.  Effects of glycyrrhizin, an active component of licorice roots, on Candida albicans infection in thermally injured mice.

Authors:  T Utsunomiya; M Kobayashi; D N Herndon; R B Pollard; F Suzuki
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  A genetic mechanism for deletion of the ser2 gene cluster and formation of rough morphological variants of Mycobacterium avium.

Authors:  T M Eckstein; J M Inamine; M L Lambert; J T Belisle
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

5.  Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Gerri S Hall; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

6.  Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients.

Authors:  Z Toossi; H Mayanja-Kizza; C S Hirsch; K L Edmonds; T Spahlinger; D L Hom; H Aung; P Mugyenyi; J J Ellner; C W Whalen
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

7.  Interleukin-12-secreting fibroblasts are more efficient than free recombinant interleukin-12 in inducing the persistent resistance to Mycobacterium avium complex infection.

Authors:  B Y Kang; S W Chung; Y S Lim; E J Kim; S H Kim; S Y Hwang; T S Kim
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

8.  Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

9.  Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Authors:  Ozlem Equils; Alan Shapiro; Zeynep Madak; Chunren Liu; Daning Lu
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Authors:  Amanda Mocroft; Jonathan A C Sterne; Matthias Egger; Margaret May; Sophie Grabar; Hansjakob Furrer; Caroline Sabin; Gerd Fatkenheuer; Amy Justice; Peter Reiss; Antonella d'Arminio Monforte; John Gill; Robert Hogg; Fabrice Bonnet; Mari Kitahata; Schlomo Staszewski; Jordi Casabona; Ross Harris; Michael Saag
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.